Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia

NCT00322452 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00322452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2010
Enrollment
1,329 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer